Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
Annals of Rheumatic Diseases,

Smolen JS et al. – In patients with active rheumatoid arthritis (RA) who discontinued previous TNF–antagonist treatment, golimumab 50 and 100 mg injections every 4 weeks yielded sustained improvements in signs/symptoms and physical function in 57–67% of patients who continued treatment. Golimumab safety was consistent with other anti–TNF agents, although definitive conclusions regarding long–term safety require further monitoring.

Methods
  • Results through week 24 of this multicentre, randomised, double–blind, placebo–controlled study of active RA (≥ 4 tender, ≥ 4 swollen joints) were previously reported.
  • Patients received placebo (Group 1), 50 mg golimumab (Group 2) or 100 mg golimumab (Group 3) subcutaneous injections every 4 weeks.
  • Patients from Groups 1 and 2 with <20% improvement in tender/swollen joints at week 16 early escaped to golimumab 50 mg and 100 mg, respectively.
  • At week 24, Group 1 patients crossed over to golimumab 50 mg, Group 2 continued golimumab 50/100 mg per escape status and Group 3 maintained dosing..
  • Data through week 160 are reported

Results
  • 459 of the 461 randomised patients were treated; 236/459 (51%) continued treatment through week 160.
  • From week 24 to week 100, ACR20 (≥ 20% improvement in American College of Rheumatology criteria) response and ≥ 0.25 unit HAQ (Health Assessment Questionnaire) improvement were sustained in 70–73% and 75–81% of responding patients, respectively.
  • Overall at week 160, 63%, 67% and 57% of patients achieved ACR20 response and 59%, 65% and 64% had HAQ improvement ≥ 0.25 unit in Groups 1, 2 and 3, respectively.
  • Adjusted for follow–up duration, adverse event incidences (95% CI) per 100 patient–years among patients treated with golimumab 50 mg and 100 mg were 4.70 (2.63 to 7.75) and 8.07 (6.02 to 10.58) for serious infection, 0.95 (0.20 to 2.77) and 2.04 (1.09 to 3.49) for malignancy and 0.00 (0.00 to 0.94) and 0.62 (0.17 to 1.59) for death, respectively.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Rheumatology Articles

1 Rituximab for the treatment of relapses in ANCA-associated vasculitis Arthritis & Rheumatism, August 1, 2014    Clinical Article

2 Oral bisphosphonate use and total knee/hip implant survival: Validation of results in an external population-based cohort Arthritis & Rheumatism, August 14, 2014    Clinical Article

3 Ultrasound-detected musculoskeletal urate crystal deposition: Which joints and what findings should be assessed for diagnosing gout? Annals of Rheumatic Diseases, July 14, 2014    Clinical Article

4 Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: A randomised, multicentre, double-blind, placebo-controlled trial Annals of Rheumatic Diseases, August 25, 2014    Clinical Article

5 Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: Outcomes of a randomised Phase IIb study Annals of Rheumatic Diseases, August 12, 2014    Clinical Article

6 Sugar-sweetened soda consumption and risk of developing rheumatoid arthritis in women American Journal of Clinical Nutrition, July 18, 2014    Review Article

7 Old medications and new targeted therapies in systemic sclerosis Rheumatology, August 4, 2014    Review Article

8 Homeopathy in the treatment of fibromyalgia- A comprehensive literature-review and meta-analysis Complementary Therapies in Medicine, August 15, 2014    Evidence Based Medicine    Review Article

9 Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: A nationwide cohort study Annals of Rheumatic Diseases, July 14, 2014    Clinical Article

10 Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial) Annals of Rheumatic Diseases, August 26, 2014    Clinical Article

11 More ubiquitous effects from non-pharmacologic than from pharmacologic treatments for fibromyalgia syndrome: A meta-analysis examining six core symptoms European Journal of Pain, August 20, 2014    Review Article

12 Clinical features, treatment and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis A multinational, multicenter study of 362 patients Arthritis & Rheumatism, August 4, 2014    Clinical Article

13 Rituximab in primary Sjogren's syndrome: A ten-year journey Lupus, August 8, 2014    Clinical Article

14 Comparison of radiological and clinical results of balloon kyphoplasty according to anterior height loss in the osteoporotic vertebral fracture The Spine Journal, August 1, 2014    Clinical Article

15 Methotrexate and lung disease in rheumatoid arthritis – A meta-analysis of randomized controlled trials Arthritis & Rheumatism, December 27, 2013    Evidence Based Medicine    Review Article    Clinical Article

16 Epidemiology of primary Sjogren's syndrome: A systematic review and meta-analysis Annals of Rheumatic Diseases, August 29, 2014    Evidence Based Medicine    Review Article

17 TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: A nationwide cohort study Annals of Rheumatic Diseases, August 29, 2014    Clinical Article

18 The incidence of secondary vertebral fracture of vertebral augmentation techniques versus conservative treatment for painful osteoporotic vertebral fractures: A systematic review and meta-analysis Acta Radiologica, August 22, 2014    Evidence Based Medicine    Review Article    Clinical Article

19 Low-field magnetic resonance imaging or combined ultrasonography and anti-cyclic citrullinated peptide antibody improve correct classification of individuals as established rheumatoid arthritis: results of a population-based, cross-sectional study Full Text BMC Musculoskeletal Disorders, August 8, 2014    Free full text    Evidence Based Medicine    Clinical Article

20 Sirukumab, a human anti-interleukin-6 monoclonal antibody: A randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy Annals of Rheumatic Diseases, August 11, 2014    Clinical Article

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close